458 related articles for article (PubMed ID: 17468032)
1. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
Vitoux D; Nasr R; de The H
Int J Biochem Cell Biol; 2007; 39(6):1063-70. PubMed ID: 17468032
[TBL] [Abstract][Full Text] [Related]
2. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Grimwade D; Mistry AR; Solomon E; Guidez F
Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
[TBL] [Abstract][Full Text] [Related]
3. Autophagic degradation of an oncoprotein.
Bøe SO; Simonsen A
Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820
[TBL] [Abstract][Full Text] [Related]
4. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission.
Zhu J; Lallemand-Breitenbach V; de Thé H
Oncogene; 2001 Oct; 20(49):7257-65. PubMed ID: 11704854
[TBL] [Abstract][Full Text] [Related]
5. Curing APL: differentiation or destruction?
Kogan SC
Cancer Cell; 2009 Jan; 15(1):7-8. PubMed ID: 19111876
[TBL] [Abstract][Full Text] [Related]
6. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
Nasr R; de Thé H
Int J Hematol; 2010 Jun; 91(5):742-7. PubMed ID: 20455087
[TBL] [Abstract][Full Text] [Related]
7. Triple A therapy: the molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide.
Nichol JN; Garnier N; Miller WH
Best Pract Res Clin Haematol; 2014 Mar; 27(1):19-31. PubMed ID: 24907014
[TBL] [Abstract][Full Text] [Related]
8. All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene.
Strehl S; König M; Boztug H; Cooper BW; Suzukawa K; Zhang SJ; Chen HY; Attarbaschi A; Dworzak MN
Leukemia; 2013 Jul; 27(7):1606-10. PubMed ID: 23271512
[No Abstract] [Full Text] [Related]
9. Curing APL through PML/RARA degradation by As2O3.
Lallemand-Breitenbach V; Zhu J; Chen Z; de Thé H
Trends Mol Med; 2012 Jan; 18(1):36-42. PubMed ID: 22056243
[TBL] [Abstract][Full Text] [Related]
10. Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity.
Ng Liet Hing M; Ryland GL; Nguyen T; Tiong IS; Dun K; Ninkovic S; Nedumannil R; Westerman DA; Blombery PA; Chan KL; Bajel A
Br J Haematol; 2023 Aug; 202(4):893-896. PubMed ID: 37280781
[No Abstract] [Full Text] [Related]
11. [Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells].
Guo W; Wang H; Zhao W
Zhonghua Yi Xue Za Zhi; 2000 May; 80(5):327-31. PubMed ID: 11798779
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide may improve the prognosis of APL with ider(17)(q10): report of a rare adult case of acute promyelocytic leukemia with ider(17)(q10)t(15;17) showing poor response to all-trans retinoic acid.
Tong H; Li K; Mei C; Wang H; Chen Z; Jin J
Ann Hematol; 2011 Dec; 90(12):1493-4. PubMed ID: 21431323
[No Abstract] [Full Text] [Related]
13. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.
Nasr R; Guillemin MC; Ferhi O; Soilihi H; Peres L; Berthier C; Rousselot P; Robledo-Sarmiento M; Lallemand-Breitenbach V; Gourmel B; Vitoux D; Pandolfi PP; Rochette-Egly C; Zhu J; de Thé H
Nat Med; 2008 Dec; 14(12):1333-42. PubMed ID: 19029980
[TBL] [Abstract][Full Text] [Related]
14. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
15. PML nuclear bodies mediate the therapeutic response of APL cells.
Cancer Discov; 2014 Mar; 4(3):OF20. PubMed ID: 24596215
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond.
Chen SJ; Zhou GB
IUBMB Life; 2012 Aug; 64(8):671-5. PubMed ID: 22714999
[TBL] [Abstract][Full Text] [Related]
17. Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
Sasaki M; Sugimoto K; Isobe Y; Oshimi K
Eur J Haematol; 2008 Aug; 81(2):160. PubMed ID: 18363868
[No Abstract] [Full Text] [Related]
18. What is the role of arsenic in newly diagnosed APL?
Tallman MS
Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605
[TBL] [Abstract][Full Text] [Related]
19. Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
Thomas X; Pigneux A; Raffoux E; Huguet F; Caillot D; Fenaux P
Haematologica; 2006 Jul; 91(7):996-7. PubMed ID: 16757416
[TBL] [Abstract][Full Text] [Related]
20. Arsenic and apoptosis in the treatment of acute promyelocytic leukemia.
Look AT
J Natl Cancer Inst; 1998 Jan; 90(2):86-8. PubMed ID: 9450562
[No Abstract] [Full Text] [Related]
[Next] [New Search]
